Get started
Author

Raffaella Giambalvo

Observed name: R. Giambalvo
Observed institution: F-star (United Kingdom)
OpenAlex ID: A5041511037
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2020 · Matthew A. Lakins, Alexander Koers, et al. · Clinical Cancer Research · 65
573 FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies
2021 · Matthew Lakins, Wenjia Liao, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 4547: Clustering CD137 via cell-expressed PD-L1 crosslinking avoided Fc-mediated agonism and resulted in safe and potent conditional lymphocyte activation
2020 · Matthew A. Lakins, Alexander Koers, et al. · Cancer Research · 1
Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile
2019 · Matthew A. Lakins, Alexander Koers, et al. · Immunology · 1
Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile
2019 · Matthew A. Lakins, Alexander Koers, et al. · Cancer Research · 1
Combined Supplementary Data from FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2023 · Matthew A. Lakins, Alexander Koers, et al.
Combined Supplementary Data from FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2023 · Matthew A. Lakins, Alexander Koers, et al.
Data from FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2023 · Matthew A. Lakins, Alexander Koers, et al.
Data from FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2023 · Matthew A. Lakins, Alexander Koers, et al.
Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody
2018 · M.A. Lakins, J. Munoz-Olaya, et al. · Annals of Oncology
Works count: 10
Citation count: 69
H-index: 1
I10-index: 1
Year
Topic
Type